| 胆管癌代谢组学研究进展 |
| 投稿时间：2022-11-09 修订日期：2023-04-28 点此下载全文 |
| 引用本文：何永平,焦杨,刘悦.胆管癌代谢组学研究进展[J].药学实践杂志,2023,41(12):705~709,732 |
| 摘要点击次数: 151 |
| 全文下载次数: 308 |
|
| 基金项目:上海市科学技术委员会“启明星”项目（21QA 1411600） |
|
| 中文摘要:胆管癌（CCA）恶性程度高，由于早期缺乏典型症状且尚无准确的生物标志物，发现时常处于晚期，预后较差。胆管癌的发生发展与代谢密切相关，代谢组学是研究在病理生理或基因修饰等因素影响下，生物体内内源性小分子代谢物变化的学科，具有全局分析、高通量和反映生物体系实时变化的特点，可以为胆管癌生物标志物的筛选、疾病诊疗提供新途径。综述近年来代谢组学在胆管癌方面的研究进展，以期为进一步研究提供参考。 |
| 中文关键词:胆管癌 代谢组学 生物标志物 发病机制 早期诊断 药效评价 |
| |
| Advances in metabolomics of cholangiocarcinoma |
|
|
| Abstract:As a highly malignant tumor, the diagnosis of cholangiocarcinoma (CCA) is often late and the prognosis is poor for which the early symptoms are atypical and the lack of accurate biomarkers. Metabolomics is an emerging science that researches the alterations of all endogenous small molecule metabolites in an organism under the influence of pathological, physiological or genetic modification. The development and progress of CCA is closely related to metabolism. Metabolomic is characterized by global analysis, high throughput and reflects real-time alterations in biology system, providing a new avenue for biomarker screening and diseases diagnosis and treatment. The advances of metabolomics studies on CCA in the recent years were reviewed in this paper which could provide the reference for further research. |
| keywords:cholangiocarcinoma metabolomic biomarkers mechanism early diagnosis pharmacodynamic evaluation |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
